Latest news with #DeepTMS
Yahoo
6 days ago
- Business
- Yahoo
Relief Mental Health Opens First Colorado Clinic in Denver, Expanding Access to Rapid, Innovative Care
DENVER, May 28, 2025 /PRNewswire/ -- Relief Mental Health, an award-winning outpatient provider of innovative mental health services, proudly announces the opening of its 12th clinic—and first in Colorado—now serving patients in Denver. This expansion brings Relief's mission of expedited, personalized care to a state where mental health is a serious challenge and needs are urgent and growing. The Denver clinic launches with two core services: transcranial magnetic stimulation (TMS) administered by a board-certified psychiatrist and therapy provided by licensed professional counselor. Additional offerings, including SPRAVATO® (esketamine) and psychiatric medication management, will be introduced in the coming months. "Mental health doesn't wait—and neither should patients," said Susan Mueller, founder and CEO at Relief Mental Health, which opened in January 2020 in Oak Brook, Illinois. "We're committed to seeing new patients within a week of their first call, if not days, because timely access can make all the difference." Cutting-Edge Treatments Provide Relief TMS is a non-invasive, FDA-cleared treatment that uses magnetic pulses to stimulate areas of the brain associated with mood regulation. It is primarily used to treat depression and/or obsessive-compulsive disorder (OCD), especially in individuals who have not responded to traditional treatments like medication or talk therapy. Using BrainsWay Deep TMS™ technology, Relief's care is the most advanced and effective treatment available. Deep TMS is administered in a clinical setting, where patients sit comfortably while a specialized helmet delivers targeted magnetic stimulation to deeper brain structures. Treatments are typically done five days a week over several weeks, with sessions lasting about 20 minutes. Deep TMS is well-tolerated, does not require anesthesia, and allows patients to return to their daily activities immediately after. It is suitable for individuals seeking a medication-free, evidence-based approach to managing persistent depression or OCD symptoms. When medical criteria are met, Deep TMS is typically covered by insurance, making this advanced treatment an accessible option for individuals who qualify. Addressing Colorado's Mental Health Crisis Colorado faces significant mental health challenges. According to the 2023 Colorado Health Access Survey, more than one in four Coloradans reported poor mental health, the highest rate ever recorded by the survey. Furthermore, 17 percent of residents—approximately 880,000 people—said they were unable to get the mental health care they needed, with more than half citing the inability to secure timely appointments as the primary barrier. The situation is particularly acute among younger adults and marginalized communities. More than a third of individuals aged 18-50 reported serious mental health challenges, and LGBTQ+ Coloradans experienced poor mental health at a rate of 54.4 percent, nearly double that of their straight and cisgender counterparts, according to the Colorado Health Institute. Access issues are compounded by a shortage of mental health professionals. The Colorado Health Institute reports that 2.8 million Coloradans—48 percent of the state's population—live in areas designated as Mental Health Professional Shortage Areas. Relief's Commitment to Expedited, Personalized Care Relief Mental Health is dedicated to bridging these gaps by offering prompt, individualized treatment. With a focus on evidence-based therapies and an empathetic approach, Relief aims to reduce the burden of mental health diagnoses in Colorado communities. For more information about Relief Mental Health or to schedule a consultation, individuals can call 855.205.4764, email info@ or visit About Relief Mental Health Relief Mental Health is a leading outpatient provider of transcranial magnetic stimulation (TMS), SPRAVATO® (esketamine), ketamine infusions, psychiatry, and therapy, for the treatment of depression, obsessive-compulsive disorder, anxiety and other diagnoses. Founded in January 2020 and dedicated to delivering expedited care, Relief has 12 facilities in four states. Relief aims to create a new standard for mental health care, offering a continuum of innovative therapeutic interventions and responding to evolving patient needs. For more information, visit CONTACT: Melanie EilersChief Marketing Officermelanie@ View original content to download multimedia: SOURCE Relief Mental Health
Yahoo
6 days ago
- Business
- Yahoo
Relief Mental Health Opens First Colorado Clinic in Denver, Expanding Access to Rapid, Innovative Care
DENVER, May 28, 2025 /PRNewswire/ -- Relief Mental Health, an award-winning outpatient provider of innovative mental health services, proudly announces the opening of its 12th clinic—and first in Colorado—now serving patients in Denver. This expansion brings Relief's mission of expedited, personalized care to a state where mental health is a serious challenge and needs are urgent and growing. The Denver clinic launches with two core services: transcranial magnetic stimulation (TMS) administered by a board-certified psychiatrist and therapy provided by licensed professional counselor. Additional offerings, including SPRAVATO® (esketamine) and psychiatric medication management, will be introduced in the coming months. "Mental health doesn't wait—and neither should patients," said Susan Mueller, founder and CEO at Relief Mental Health, which opened in January 2020 in Oak Brook, Illinois. "We're committed to seeing new patients within a week of their first call, if not days, because timely access can make all the difference." Cutting-Edge Treatments Provide Relief TMS is a non-invasive, FDA-cleared treatment that uses magnetic pulses to stimulate areas of the brain associated with mood regulation. It is primarily used to treat depression and/or obsessive-compulsive disorder (OCD), especially in individuals who have not responded to traditional treatments like medication or talk therapy. Using BrainsWay Deep TMS™ technology, Relief's care is the most advanced and effective treatment available. Deep TMS is administered in a clinical setting, where patients sit comfortably while a specialized helmet delivers targeted magnetic stimulation to deeper brain structures. Treatments are typically done five days a week over several weeks, with sessions lasting about 20 minutes. Deep TMS is well-tolerated, does not require anesthesia, and allows patients to return to their daily activities immediately after. It is suitable for individuals seeking a medication-free, evidence-based approach to managing persistent depression or OCD symptoms. When medical criteria are met, Deep TMS is typically covered by insurance, making this advanced treatment an accessible option for individuals who qualify. Addressing Colorado's Mental Health Crisis Colorado faces significant mental health challenges. According to the 2023 Colorado Health Access Survey, more than one in four Coloradans reported poor mental health, the highest rate ever recorded by the survey. Furthermore, 17 percent of residents—approximately 880,000 people—said they were unable to get the mental health care they needed, with more than half citing the inability to secure timely appointments as the primary barrier. The situation is particularly acute among younger adults and marginalized communities. More than a third of individuals aged 18-50 reported serious mental health challenges, and LGBTQ+ Coloradans experienced poor mental health at a rate of 54.4 percent, nearly double that of their straight and cisgender counterparts, according to the Colorado Health Institute. Access issues are compounded by a shortage of mental health professionals. The Colorado Health Institute reports that 2.8 million Coloradans—48 percent of the state's population—live in areas designated as Mental Health Professional Shortage Areas. Relief's Commitment to Expedited, Personalized Care Relief Mental Health is dedicated to bridging these gaps by offering prompt, individualized treatment. With a focus on evidence-based therapies and an empathetic approach, Relief aims to reduce the burden of mental health diagnoses in Colorado communities. For more information about Relief Mental Health or to schedule a consultation, individuals can call 855.205.4764, email info@ or visit About Relief Mental Health Relief Mental Health is a leading outpatient provider of transcranial magnetic stimulation (TMS), SPRAVATO® (esketamine), ketamine infusions, psychiatry, and therapy, for the treatment of depression, obsessive-compulsive disorder, anxiety and other diagnoses. Founded in January 2020 and dedicated to delivering expedited care, Relief has 12 facilities in four states. Relief aims to create a new standard for mental health care, offering a continuum of innovative therapeutic interventions and responding to evolving patient needs. For more information, visit CONTACT: Melanie EilersChief Marketing Officermelanie@ View original content to download multimedia: SOURCE Relief Mental Health
Yahoo
14-05-2025
- Business
- Yahoo
BrainsWay Ltd (BRSYF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Market Expansion
Revenue: $11.5 million in Q1 2025, a 27% increase year-over-year. Deep TMS Systems Shipped: 81 systems in Q1 2025, a 42% increase compared to Q1 2024. Installed Base: 1,434 systems as of March 31, 2025, up from 1,158 systems a year earlier. Gross Margin: 75% in Q1 2025, consistent with the prior year period. Operating Profit: Approximately $576,000 in Q1 2025, up from $93,000 in Q1 2024. Adjusted EBITDA: $1.3 million in Q1 2025, compared to $715,000 in Q1 2024. Net Profit: $1.1 million in Q1 2025, compared to $111,000 in Q1 2024. Cash, Cash Equivalents, and Short-term Deposits: Approximately $72 million as of March 31, 2025. Sales and Marketing Expenses: $4.2 million in Q1 2025, up from $3.8 million in Q1 2024. Research and Development Expenses: $2.3 million in Q1 2025, compared to $1.6 million in Q1 2024. General and Administrative Expenses: $1.5 million in Q1 2025, compared to $1.3 million in Q1 2024. Full Year 2025 Revenue Guidance: $49 million to $51 million, representing 20% to 24% growth over 2024. Full Year 2025 Operating Profit Guidance: 3% to 4% of revenue. Full Year 2025 Adjusted EBITDA Guidance: 11% to 12% of revenue. Warning! GuruFocus has detected 3 Warning Signs with BRSYF. Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. BrainsWay Ltd (BRSYF) reported a 27% year-over-year increase in revenue for Q1 2025, reaching $11.5 million. The company shipped 81 Deep TMS systems in Q1 2025, a 42% increase compared to the same period in 2024. BrainsWay Ltd (BRSYF) has a backlog and remaining performance obligation totaling nearly $60 million, providing visibility into future growth. The company maintains a strong gross margin of 75%, reflecting effective expense management. BrainsWay Ltd (BRSYF) continues to expand its market presence, particularly in the US, with increased adoption of Deep TMS for OCD and anxious depression treatments. Sales and marketing expenses increased to $4.2 million in Q1 2025 from $3.8 million in Q1 2024. Research and development expenses rose to $2.3 million in Q1 2025 from $1.6 million in the same period of 2024. General and administrative expenses increased to $1.5 million in Q1 2025 compared to $1.3 million in Q1 2024. The company is actively monitoring potential exposure to changes in international trade and tariff policies, which could impact operations. BrainsWay Ltd (BRSYF) has not yet implemented a stock repurchase program, despite having $72 million in cash and equivalents. Q: Can you provide insights into the market expansion versus competitive conversions for your systems? A: (Hadar Levy, CEO) Approximately 80% of our new sales are from greenfield opportunities, meaning new customers, while 20% are conversions from competitors. Some new systems also come from expanding our current customer base. Q: Could you elaborate on the shift towards sustainable revenue models like lease and pay-per-use? A: (Hadar Levy, CEO) In Israel, we use a pay-per-use model, providing systems with no upfront fee and charging per procedure. In the US, we offer both pay-per-use and fixed contracts, with the latter being preferred by high-volume clinics. Q: When do you expect data from the accelerated protocol clinical trials, and any updates on trials with psychedelic drugs? A: (Hadar Levy, CEO) We expect FDA clearance for the accelerated protocol by year-end. We are also collecting data for PTSD and adolescent MDD treatments, aiming for FDA submission and clearance this year. We plan to launch a clinical trial combining Deep TMS with psychedelic treatments in Q3. Q: Are there any significant geopolitical risks affecting your business? A: (Hadar Levy, CEO) We are actively monitoring geopolitical changes and tariff policies but do not foresee any negative impact on our industry. The environment remains positive for us. Q: Are there plans for a stock repurchase program? A: (Hadar Levy, CEO) Currently, we are not considering a stock repurchase program. We are focused on expanding revenue growth and investing in innovation. We will evaluate this option towards the end of the year. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
